



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

January 15, 2013 6:00 – 8:30 p.m.

- 1. Executive Session** **6:00 - 6:30**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:45**
 - Updates

- 4. Medical Director Update** **6:45 - 6:45**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:45 - 7:00**
 - Antipsychotic Medications in Children - Survey
 - Practice Change Strategies
 - Displaying Prior Authorization End Dates to Pharmacies

- 6. RetroDUR/DUR** **7:00 – 7:30**
 - Narcotic Analgesics – continued use of short acting with no long acting
 - Skeletal Muscle Relaxants

- 7. Clinical Update: Drug Reviews** **7:30 – 7:45**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Binosto[®] (alendronate sodium) effervescent tablet
 - Rayos[®] (prednisone) delayed release tablet

 - Full New Drug Reviews**
 - Eleyso[®] (taliglucerase alfa) vial for injection

- 8. Therapeutic Drug Classes – Periodic Review** **7:45 – 8:15**
(Public comment prior to Board action)
Class review documents available on DVHA web site 01/15/2013 @ 12 Noon
- Antidepressants: SNRI and Miscellaneous
 - Gastrointestinal: Proton Pump Inhibitors
 - Ophthalmic Immunomodulators (Restasis®)
 - Pancreatic Enzymes (including new drug reviews of Pertzye®, Ultresa® and Viokace®)
- 9. New Managed Therapeutic Drug Classes** **8:15 – 8:20**
(Public comment prior to Board action)
- Gastrointestinal: Anti-ulcer: H.Pylori Combination Therapy
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:20 – 8:20**
(Public comment prior to Board action)
- None
- 11. General Announcements** **8:20– 8:30**
Selected FDA Safety Alerts
- Chantix (varenicline): Safety review update of the risk of cardiovascular adverse events
 - Incivek (telaprevir): Serious skin reactions after used in combination treatment with the Hepatitis C drugs peginterferon alfa, and ribavirin
 - Pradaxa (dabigatran etexilate mesylate): Not be used in patients with mechanical prosthetic heart valves
 - Xyrem (sodium oxybate): Warning against use with alcohol or drugs causing respiratory depression
- 12. Adjourn** **8:30**